# A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

> **NCT07662109** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 2000 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Elecoglipron
- **DRUG:** Dapagliflozin
- **DRUG:** Elecoglipron-matched placebo
- **DRUG:** Dapagliflozin-matched placebo

## Key facts

- **NCT ID:** NCT07662109
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2028-07-05
- **Final completion:** 2028-07-05
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662109, "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*